| 3.92 -0.03 (-0.76%) | 04-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.28 |
1-year : | 5.82 |
| Resists | First : | 4.52 |
Second : | 4.98 |
| Pivot price | 4.1 |
|||
| Supports | First : | 3.76 | Second : | 3.13 |
| MAs | MA(5) : | 3.89 |
MA(20) : | 4.2 |
| MA(100) : | 5.74 |
MA(250) : | 6.39 |
|
| MACD | MACD : | -0.3  |
Signal : | -0.3 |
| %K %D | K(14,3) : | 21.2 |
D(3) : | 16.3 |
| RSI | RSI(14): 27.8 |
|||
| 52-week | High : | 7.98 | Low : | 3.76 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MDXG ] has closed above bottom band by 25.4%. Bollinger Bands are 25.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.94 - 3.97 | 3.97 - 3.99 |
| Low: | 3.75 - 3.78 | 3.78 - 3.8 |
| Close: | 3.88 - 3.92 | 3.92 - 3.96 |
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Fri, 03 Apr 2026
MiMedx Group (MDXG) delivers record full year revenue - MSN
Thu, 02 Apr 2026
MIMEDX to Sponsor Leading Advanced Wound Care Conferences - ChartMill
Thu, 02 Apr 2026
MIMEDX takes platinum sponsor role at limb salvage conference - Stock Titan
Thu, 02 Apr 2026
MIMEDX to Sponsor Leading Advanced Wound Care Conferences - Yahoo Finance Singapore
Mon, 23 Mar 2026
MIMEDX Announces Launch of CHORIOFIX™ - GlobeNewswire
Mon, 23 Mar 2026
MiMedx adds its thickest graft yet for deep, hard-to-treat wounds - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 149 (M) |
| Shares Float | 118 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 73.1 (%) |
| Shares Short | 6,180 (K) |
| Shares Short P.Month | 7,290 (K) |
| EPS | 0.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.73 |
| Profit Margin | 11.6 % |
| Operating Margin | 17.8 % |
| Return on Assets (ttm) | 13.1 % |
| Return on Equity (ttm) | 21.6 % |
| Qtrly Rev. Growth | 27.1 % |
| Gross Profit (p.s.) | 2.32 |
| Sales Per Share | 2.81 |
| EBITDA (p.s.) | 0.53 |
| Qtrly Earnings Growth | 99.5 % |
| Operating Cash Flow | 74 (M) |
| Levered Free Cash Flow | 63 (M) |
| PE Ratio | 12.25 |
| PEG Ratio | 0 |
| Price to Book value | 2.26 |
| Price to Sales | 1.39 |
| Price to Cash Flow | 7.87 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|